Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults
Public ClinicalTrials.gov record NCT04370054. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants With Moderately Severe to Severe Hemophilia A(FVIII:C≤1%)
Study identification
- NCT ID
- NCT04370054
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 77 participants
Conditions and interventions
Conditions
Interventions
- PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 64 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 17, 2020
- Primary completion
- Jun 16, 2024
- Completion
- Oct 24, 2028
- Last update posted
- Aug 16, 2025
2020 – 2028
United States locations
- U.S. sites
- 11
- U.S. states
- 2
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NOW Physical Therapy | Mountain View | California | 94040 | — |
| Clinical and Translational Research Unit (CTRU) | Palo Alto | California | 94304 | — |
| Lucile Packard Childrens Hospital | Palo Alto | California | 94304 | — |
| Imaging Clinic at Stanford Medicine Outpatient Center in Redwood City | Redwood City | California | 94063 | — |
| UCSF IDS Pharmacy | San Francisco | California | 94143 | — |
| University of California, San Francisco - Clinical Research Center | San Francisco | California | 94143 | — |
| University of California, San Francisco - Moffitt/Long Inpatient Hematology | San Francisco | California | 94143 | — |
| University of California, San Francisco - Outpatient Hematology Clinic | San Francisco | California | 94143 | — |
| Stanford Health Care | Stanford | California | 94305 | — |
| Washington Institute for Coagulation | Seattle | Washington | 98101 | — |
| University of Washington Medical Center - Translational Research Unit (TRU) | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04370054, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 16, 2025 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04370054 live on ClinicalTrials.gov.